Custom Search

News

Monday 01 August 2005

Chronic relapsing thrombotic thrombocytopenic purpura successfully treated with rituximab: case report.

By: Gianfaldoni G, Antonioli E, Mannelli F, Vannucchi AM, Bosi A.

J Chemother 2005 Aug;17(4):449-51

Plasma therapy is a cornerstone in the treatment of idiopathic Thrombotic Thrombocytopenic Purpura (TTP); however about one-third of patients relapse. In this subset of patients different immunosuppressive approaches have been reported with variable efficacy. We describe the case of an 11-year-long chronic relapsing TTP, requiring frequent plasma exchange procedures and treated unsuccessfully with several immunosuppressive agents. On the occasion of a further relapse, the patient was treated with rituximab, and achieved normalization of hematological values and clinical status for about one year. Upon further relapse, rituximab therapy was started again successfully. A monthly administration was performed with the aim of maintaining the clinical and hematological response stable. In conclusion, rituximab is a safe and effective alternative to other immunosuppressive therapies for chronic relapsing TTP patients.

Use of this site is subject to the following terms of use